We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04526496




Registration number
NCT04526496
Ethics application status
Date submitted
9/03/2020
Date registered
25/08/2020
Date last updated
9/02/2021

Titles & IDs
Public title
Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers
Scientific title
A 2-part, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of FTP-198 in Healthy Volunteers
Secondary ID [1] 0 0
FTP198-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - FTP-198, single dose
Treatment: Drugs - Placebo, single dose
Treatment: Drugs - FTP-198, multiple doses
Treatment: Drugs - Placebo, multiple doses

Experimental: Single Ascending Doses - 50mg-600mg

Experimental: Multiple Ascending Doses - dose to be determined


Treatment: Drugs: FTP-198, single dose
Single dose of FTP-198, 6 dose levels, oral suspension

Treatment: Drugs: Placebo, single dose
Placebo matched to FTP-198, oral suspension

Treatment: Drugs: FTP-198, multiple doses
Multiple doses of FTP-198, 3 dose levels, oral suspension, 7 days

Treatment: Drugs: Placebo, multiple doses
Placebo matched to FTP-198, oral suspension, 7 days

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The number and severity of treatment emergent adverse events (TEAEs) - To assess the safety and tolerability of single and multiple ascending oral doses of FTP-198 in healthy Australian subjects
Timepoint [1] 0 0
7 days after the last doses
Secondary outcome [1] 0 0
Cmax - peak palsma concentration
Timepoint [1] 0 0
within 0.5 hours before administration until 48 hours after administration
Secondary outcome [2] 0 0
AUC - area under the plasma concentration versus time curve
Timepoint [2] 0 0
within 0.5 hours before administration until 48 hours after administration
Secondary outcome [3] 0 0
t1/2 - half-life
Timepoint [3] 0 0
within 0.5 hours before administration until 48 hours after administration
Secondary outcome [4] 0 0
The level of changes of pharmacodynamic biomarkers - The change-from-baseline values of plasma lysophosphatidic acid (LPA) as PD biomarkers
Timepoint [4] 0 0
within 0.5 hours before administration until 24 hours (single dose) or 48 hours (multiple doses) after administration

Eligibility
Key inclusion criteria
1. Must have given written informed consent before any study-related activities are
carried out and must be able to understand the full nature and purpose of the trial,
including possible risks and adverse effects;

2. Adult males and females, 18 to 55 years of age (inclusive) at screening;

3. Body mass index = 18.0 and = 30.0 kg/m2, with a body weight = 50 kg at screening;

4. Be nonsmokers (including tobacco, e-cigarettes and marijuana) for at least 1 month
prior to first study drug administration;

5. Medically healthy without clinically significant abnormalities at screening and
predose on Day 1, including:

1. Physical examination without any clinically relevant findings;

2. Systolic blood pressure in the range of 90 to 160 mmHg and diastolic blood
pressure in the range of 50 to 95 mmHg after 5 minutes in supine position;

3. Heart rate in the range of 50 to 100 bpm after 5 minutes rest in supine position;

4. Body temperature, between 35.0°C and 37.5°C;

5. No clinically significant findings in serum chemistry, hematology, coagulation
and urinalysis tests as judged by the investigator;

6. Conventional 12-lead ECG recording in triplicate (the mean of triplicate measurements
will be used to determine eligibility at screening and predose on Day 1) consistent
with normal cardiac conduction and function, including:

- Normal sinus rhythm with HR between 50 and 100 bpm, inclusive;

- QT interval corrected using the Fridericia method (QTcF) between 350 to 450 msec
for male subjects and 350 to 470 msec for female subjects, inclusive;

- QRS duration of < 120 msec;

- PR interval of = 210 msec;

- Electrocardiogram morphology consistent with healthy cardiac ventricular
conduction and normal rhythm, and with measurement of the QT interval;

- No family history of short or long QT syndrome;

- No history of risk factors for torsade de pointes or the diagnosis;

7. Female participants must:

1. Be of nonchildbearing potential ie, surgically sterilized (hysterectomy,
bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before
screening) or postmenopausal (where postmenopausal is defined as no menses for 12
months without an alternative medical cause), or

2. If of childbearing potential, must have a negative pregnancy test at screening
(blood test) and before the first study drug administration (Day -1 urine test).
They must agree not to attempt to become pregnant, must not donate ova, and must
use a highly effective contraceptive method from signing the consent form until
at least 30 days after the last dose of study drug.

8. Male participants, if not surgically sterilized, must be willing not to donate sperm
and, if engaging in sexual intercourse with a female partner who could become
pregnant, must be willing to use a condom in addition to having the female partner use
a highly effective contraceptive method from signing the consent form until at least
90 days after the last dose of study drug;

9. Have suitable venous access for blood sampling;

10. Be willing and able to comply with all study assessments and adhere to the protocol
schedule and restrictions.
Minimum age
18 Years
Maximum age
55 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological
disease, including any acute illness or surgery within the past 3 months determined by
the PI to be clinically relevant;

2. Current infection that requires antibiotic, antifungal, antiparasitic or antiviral
medications;

3. Any history of malignant disease in the last 10 years (excludes surgically resected
skin squamous cell or basal cell carcinoma);

4. Presence of clinically relevant immunosuppression from, but not limited to,
immunodeficiency conditions such as common variable hypogammaglobulinemia;

5. Use of or plans to use systemic immunosuppressive (eg, corticosteroids, methotrexate,
azathioprine, cyclosporine) or immunomodulating medications (eg, interferon) during
the study or within 4 months prior to the first study drug administration;

6. Liver function test results (ie, aspartate aminotransferase [AST], alanine
aminotransferase [ALT], and gammaglutamyl transferase [GGT]) and total bilirubin must
not be elevated more than 1.2-fold above the upper limit of normal (ULN);

7. Positive test results for active human immunodeficiency virus (HIV), hepatitis B
surface antigen (HBsAg) or hepatitis C virus (HCV) antibodies (Abs);

8. History of active, latent or inadequately treated tuberculosis infection;

9. Presence or having sequelae of gastrointestinal, liver, kidney, or other conditions
known to interfere with the absorption, distribution, metabolism, or excretion of
drugs;

10. Estimated creatinine clearance (CrCl) < 40 mL/min using the Cockcroft-Gault formula or
serum creatinine more than 1.5-fold above the ULN;

11. History of substance abuse or alcohol abuse within 12 months prior to first study drug
administration;

12. Positive drug or alcohol test results;

13. Use of any prescription or over-the-counter medication (including herbal products,
diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication
(whichever is longer) prior to the first study drug administration, except occasional
use of paracetamol;

14. Demonstrated clinically significant (required intervention, eg, emergency room visit,
epinephrine administration) allergic reactions (eg, food, drug, or atopic reactions,
asthmatic episodes) which, in the opinion of the investigator, would interfere with
the volunteer's ability to participate in the trial;

15. Known hypersensitivity to any of the study drug ingredients;

16. Use of any live vaccinations within 30 days prior to the first study drug
administration except for the influenza vaccine;

17. For women of childbearing potential, a positive serum pregnancy test at screening or a
positive urine pregnancy test with confirmatory serum pregnancy test on Day -1;

18. Donation of blood or plasma within 30 days prior to first study drug administration,
or loss of whole blood of more than 500 mL within 30 days prior to randomization, or
receipt of a blood transfusion within 1 year of first study drug administration;

19. Participation in another investigational clinical trial within 60 days prior to the
first study drug administration;

20. Any other condition or prior therapy that in the opinion of the PI would make the
volunteer unsuitable for this study, including inability to cooperate fully with the
requirements of the study protocol or likelihood of noncompliance with any study
requirements;

21. Is an employee of an investigator or sponsor or an immediate relative of an
investigator.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
CMAX Clinical Research Pty Ltd - Adelaide
Recruitment postcode(s) [1] 0 0
- Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Sichuan Haisco Pharmaceutical Group Co., Ltd
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a first-in-human, Phase I, single-dose escalation and multiple-dose escalation
clinical trial for FTP-198 conducted in Australian healthy volunteers. The safety,
tolerability, and pharmacokinetics of FTP-198 suspension in healthy volunteers will be
evaluated using a randomized, double-blind, placebo-controlled trial design.
Trial website
https://clinicaltrials.gov/show/NCT04526496
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications